AI assistant
Altimmune, Inc. — Director's Dealing 2024
Jan 30, 2024
33207_dirs_2024-01-29_ca96b1d5-2e21-4b17-a064-312a3a14699c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Altimmune, Inc. (ALT)
CIK: 0001326190
Period of Report: 2024-01-25
Reporting Person: Eisenstadt Richard I (Chief Financial Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-01-25 | Stock Options (option to buy) | $9.28 | A | 163200 | Acquired | 2034-01-25 | Common Stock, par value $0.0001 (163200) | Direct |
| 2024-01-25 | Restricted Stock Units | $ | A | 58400 | Acquired | Common Stock, par value $0.0001 (58400) | Direct |
Footnotes
F1: Twenty-five percent of the shares underlying the option become vested and exercisable on January 25, 2025 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following January 25, 2025, subject to the reporting person's continued service through the applicable vesting date.
F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.
F3: The RSUs vest in substantially equal annual installments over the 4 years following January 25, 2024, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.